- Global Pharma News & Resources

Radiopharmaceuticals Market 2021-2028 Study & Future Prospects Including key players | Cardinal Health, Curium, GENERAL ELECTRIC COMPANY, Lantheus Medical Imaging, Inc

A new market study is released on Radiopharmaceuticals Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. A number of estimations and calculations have been executed in an influential Radiopharmaceuticals Market report by assuming definite base year and the historic year. With this, businesses can think about the scene about how the market is going to act upon in the forecast years by gaining details on market definition, classifications, applications, and engagements. Moreover, this market report also provides strategic profiling of top players in the industry, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The worldwide Radiopharmaceuticals Market report contains the list of leading competitors, strategic industry analysis and the insights of key factors influencing the industry.

The Global Radiopharmaceuticals Market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 14.28 billion by 2028 and is expected to grow at a CAGR of 9.80% in the above mentioned forecast period.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @

Radiopharmaceuticals are the group of pharmaceuticals drug that have radioactivity. They are used as diagnostic and therapeutic agent. Radiopharmaceuticals are exclusive medicinal formulations containing radioisotopes and are used in major clinical area for diagnosis or therapy.

The major players covered in the radiopharmaceuticals market report are Cardinal Health, Curium, GENERAL ELECTRIC COMPANY, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Diagnostic Inc., Eczacibasi Monrol, Nordion (Canada) Inc.,  Advanced Accelerator Applications, NTP, Mallinckrodt., Eli Lilly and Company, Jubilant Pharma Limited, Actinium Pharmaceuticals, Inc., Merck & Co., Inc., Navidea Biopharmaceuticals, Inc., Eckert & Ziegler., Siemens Healthcare Private Limited, Novartis AG, and Beijing International Pharmaceutical Technology Co., Ltd., among other domestic and global players.

A first-rate Radiopharmaceuticals Market business report deals with numerous parameters in detail to suit the requirements of business or clients. This market research report has thorough analysis of market and numerous related factors that range from market drivers, market restraints, market segmentation, opportunities, challenges, and market revenues to competitive analysis. Analysis and estimations derived through the huge information collected in this market report are extremely essential when it comes to dominating the market or creating a mark in the market as a rising emergent. Radiopharmaceuticals Market research report is a truthful source of information which offers a telescopic view of the current market trends, situations, opportunities, and status.

Study Coverage:

The report defines, describes, and forecasts the Radiopharmaceuticals Market, by technology, application, and region. It also offers a detailed qualitative and quantitative analysis of the market. The report provides a comprehensive review of the major market drivers, restraints, opportunities, and challenges. It also covers various important aspects of the market, which include the analysis of the competitive landscape, market dynamics, market estimates in terms of value, and future trends in the Radiopharmaceuticals Market.

Global Radiopharmaceuticals Market Scope and Market Size

The radiopharmaceuticals market is segmented on the basis of type, application, procedural volume assessment, source, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on type, the radiopharmaceuticals market is segmented into diagnostic nuclear medicine and therapeutic nuclear medicine. Diagnostic nuclear medicine has further been segmented into SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT radiopharmaceuticals have further been sub-segmented into technetium-99m, thallium-201, gallium-67, iodine-123 and other. PET radiopharmaceuticals have further been sub-segmented intoF-18, RU-82 and others. Therapeutic nuclear medicine has further been segmented into alpha emitters, brachytherapy isotopes and beta emitters. Alpha emitters have further been sub-segmented intoRa-223. Beta emitters have further been sub-segmented intoiodine-131, yttrium-90, samarium-153, lutetium-177, rhenium-186 and other beta emitters. Brachytherapy isotopes have further been sub-segmented intoiodine-125, palladium-103, cesium-131, iridium-192 and other brachytherapy isotopes.
  • The application segment of the radiopharmaceuticals market is segmented into diagnostic applications and therapeutic applications. Diagnostic applications have further been segmented into SPECT applications and PET applications. SPECT applications have further been sub-segmented into cardiology, bone scans, thyroid applications, pulmonary scans and other SPECT applications. PET applications have further been sub-segmented into oncology, cardiology, neurology and other PET applications. Therapeutic applications have further been segmented into thyroid indications, bone metastasis, lymphoma, endocrine tumors and other indications.
  • Based on procedural volume assessment, the radiopharmaceuticals market is segmented into diagnostic procedures and therapeutic procedures. Diagnostic procedures have further been segmented into SPECT procedures and PET procedures. Therapeutic procedures have further been segmented into beta emitter procedures, alpha emitter procedures and brachytherapy procedures.
  • On the basis of source, the radiopharmaceuticals market is segmented into nuclear reactors and cyclotrons.
  • On the basis of end user, the radiopharmaceuticals market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes and others.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get FREE Detailed TOC @

Key benefits of the report

The Radiopharmaceuticals Market is also presented to the readers as a holistic snapshot of the competitive landscape within the given forecast period. The report also educates about the market strategies that are being adopted by your competitors and leading organizations. The report also focuses on all the recent industry trends. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of where areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the market.

Read More @

Healthcare Infrastructure growth Installed base and New Technology Penetration

The radiopharmaceuticals market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for radiopharmaceuticals market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the radiopharmaceuticals market. The data is available for historic period 2010 to 2019.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @

Editor Details

  • Company:
    • The Wire Times
Last Updated: 22-Oct-2021